"10.1371_journal.pone.0148760","plos one","2016-02-05T00:00:00Z","Shuya Yano; Kiyoto Takehara; Shinji Miwa; Hiroyuki Kishimoto; Yukihiko Hiroshima; Takashi Murakami; Yasuo Urata; Shunsuke Kagawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman","AntiCancer, Inc., San Diego, CA, United States of America; Department of Surgery, University of California San Diego, San Diego, CA, United States of America; Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharm Inc., Tokyo, Japan","Conceived and designed the experiments: SY RMH. Performed the experiments: SY KT SM HK. Analyzed the data: SY KT SM HK YH TM YU SK MB TF RMH. Contributed reagents/materials/analysis tools: YU TF RMH. Wrote the paper: SY TF RMH.","The authors have the following interests: Shuya Yano, Kiyoto Takehara, Shinji Miwa, Yukihiko Hiroshima, Takashi Murakami and Robert M. Hoffman are unpaid affiliates of AntiCancer Inc. Hiroyuki Kishimoto was a former unpaid affiliate of AntiCancer Inc. Robert M. Hoffman is a PLOS ONE Editorial Board Member. AntiCancer Inc. markets animal models of cancer. Yasuo Urata is President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-401. Toshiyoshi Fujiwara is a consultant of Oncolys BioPharma, Inc. There are no other competing interests. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The specific roles of these authors are articulated in the ‘author contributions’ section.","2016","02","Shuya Yano","SY",11,TRUE,2,4,11,3,TRUE,TRUE,FALSE,0,NA,FALSE
